{
  "output": {
    "structuredBrief": {
      "depth": "Medium-depth, with prioritization of current, decision-relevant payer intelligence and recent policy shifts",
      "audience": [
        "Market access leaders",
        "Commercial strategy teams",
        "Payer strategy teams",
        "Brand teams"
      ],
      "objective": "Assess current and evolving U.S. payer coverage policies for anti-obesity medications; identify drivers of favorable versus restrictive access; clarify evidence expectations for formulary inclusion and tiering; understand how payers define and measure value; and identify access barriers and differentiation opportunities.",
      "topic_type": "Market access / payer policy research",
      "assumptions": [
        "The primary focus is U.S. payer coverage for prescription anti-obesity pharmacotherapies rather than non-pharmacologic obesity management.",
        "Commercial and Medicare Advantage coverage are the most relevant payer segments; Medicaid and self-insured employer nuances are secondary unless they materially shape access.",
        "Evidence from both published sources and gray literature is in scope, including payer policy documents, conference content, and advisory-board insights.",
        "Coverage differences between pharmacy benefit and medical benefit should be captured when identifiable.",
        "Direct payer quotations may not be available for all payers; summarized perspectives are acceptable when verbatim quotes cannot be sourced.",
        "Recent means approximately the prior 12–18 months from the current date, unless older policy context is needed for comparison.",
        "Competitor analysis is limited to payer-facing value propositions rather than a full commercial review of all obesity brands."
      ],
      "geographies": [
        "United States"
      ],
      "target_topic": "U.S. payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies",
      "time_horizon": "Current state with emphasis on policy and coverage changes from the last 12–18 months",
      "output_format": "Consulting-style research brief with qualitative synthesis supported by policy documents, gray literature, and payer quotes where available",
      "target_entities": [
        "National commercial health plans",
        "Regional commercial health plans",
        "Medicare Advantage plans",
        "Pharmacy benefit managers (PBMs)",
        "Employer-sponsored health plans",
        "Manufacturers / competitors in anti-obesity therapeutics"
      ],
      "decision_context": "Inform market access strategy, payer value proposition development, and coverage/contracting approach for anti-obesity medications in the U.S. payer landscape.",
      "research_question": "How do major U.S. commercial and Medicare Advantage plans cover anti-obesity medications, what utilization management is most common, what evidence do payers prioritize for coverage and value assessment, and how are employers and competitors influencing access decisions?",
      "priority_dimension": [
        "Coverage status and formulary positioning",
        "Utilization management requirements",
        "Clinical and economic evidence requirements",
        "Long-term outcomes evidence (e.g., cardiovascular risk reduction, cost offsets)",
        "Adherence, discontinuation, and real-world effectiveness concerns",
        "Employer influence on coverage decisions",
        "Unmet payer needs",
        "Competitor value propositioning",
        "Innovative contracting models"
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"structuredBrief\":{\"research_question\":\"How do major U.S. commercial and Medicare Advantage plans cover anti-obesity medications, what utilization management is most common, what evidence do payers prioritize for coverage and value assessment, and how are employers and competitors influencing access decisions?\",\"objective\":\"Assess current and evolving U.S. payer coverage policies for anti-obesity medications; identify drivers of favorable versus restrictive access; clarify evidence expectations for formulary inclusion and tiering; understand how payers define and measure value; and identify access barriers and differentiation opportunities.\",\"topic_type\":\"Market access / payer policy research\",\"target_topic\":\"U.S. payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies\",\"target_entities\":[\"National commercial health plans\",\"Regional commercial health plans\",\"Medicare Advantage plans\",\"Pharmacy benefit managers (PBMs)\",\"Employer-sponsored health plans\",\"Manufacturers / competitors in anti-obesity therapeutics\"],\"geographies\":[\"United States\"],\"time_horizon\":\"Current state with emphasis on policy and coverage changes from the last 12–18 months\",\"decision_context\":\"Inform market access strategy, payer value proposition development, and coverage/contracting approach for anti-obesity medications in the U.S. payer landscape.\",\"priority_dimension\":[\"Coverage status and formulary positioning\",\"Utilization management requirements\",\"Clinical and economic evidence requirements\",\"Long-term outcomes evidence (e.g., cardiovascular risk reduction, cost offsets)\",\"Adherence, discontinuation, and real-world effectiveness concerns\",\"Employer influence on coverage decisions\",\"Unmet payer needs\",\"Competitor value propositioning\",\"Innovative contracting models\"],\"output_format\":\"Consulting-style research brief with qualitative synthesis supported by policy documents, gray literature, and payer quotes where available\",\"depth\":\"Medium-depth, with prioritization of current, decision-relevant payer intelligence and recent policy shifts\",\"audience\":[\"Market access leaders\",\"Commercial strategy teams\",\"Payer strategy teams\",\"Brand teams\"],\"assumptions\":[\"The primary focus is U.S. payer coverage for prescription anti-obesity pharmacotherapies rather than non-pharmacologic obesity management.\",\"Commercial and Medicare Advantage coverage are the most relevant payer segments; Medicaid and self-insured employer nuances are secondary unless they materially shape access.\",\"Evidence from both published sources and gray literature is in scope, including payer policy documents, conference content, and advisory-board insights.\",\"Coverage differences between pharmacy benefit and medical benefit should be captured when identifiable.\",\"Direct payer quotations may not be available for all payers; summarized perspectives are acceptable when verbatim quotes cannot be sourced.\",\"Recent means approximately the prior 12–18 months from the current date, unless older policy context is needed for comparison.\",\"Competitor analysis is limited to payer-facing value propositions rather than a full commercial review of all obesity brands.\"]}}",
  "providerResponseId": "resp_01481f154696fc88006a05f437f7dc819c9a035b9b3647b6e4"
}

{
  "output": {
    "researchPlan": {
      "knownRisks": [
        "Public policies may lag actual adjudication or employer-specific carve-outs",
        "Plan documents may omit rationale, requiring inference from secondary sources",
        "Some Medicare Advantage and employer decisions may be opaque or non-public",
        "Direct payer quotes may be sparse, reducing specificity of value assessment",
        "Rapid policy changes may outpace the source window",
        "Competitor claims may be promotional and not reflect payer adoption",
        "Pharmacy-benefit coverage may be easier to document than medical-benefit exceptions"
      ],
      "workstreams": [
        {
          "name": "Coverage landscape by payer segment",
          "keyQuestions": [
            "Which major U.S. commercial plans and Medicare Advantage plans cover anti-obesity medications today?",
            "What products are covered, excluded, or access-limited by plan and benefit channel?",
            "How do pharmacy vs medical benefit policies differ?",
            "What recent coverage changes occurred in the last 12–18 months?"
          ],
          "sourceClasses": [
            "Payer formulary and medical/pharmacy policy documents",
            "PBM formulary and coverage tools",
            "Plan websites and member benefits pages",
            "Policy update notices / archives",
            "Secondary trackers and payer policy databases"
          ],
          "optionalEvidence": [
            "State-by-state plan comparisons",
            "Historical policy evolution beyond 18 months",
            "Benefit design details from employer summaries"
          ],
          "requiredEvidence": [
            "Current public coverage/policy documents for priority national and regional plans",
            "Evidence of recent policy changes or launch/refresh dates"
          ],
          "analogScoringDimensions": {
            "Coverage breadth": {
              "weight": 0.35
            },
            "Access restrictiveness": {
              "weight": 0.25
            },
            "Recent policy momentum": {
              "weight": 0.2
            },
            "Benefit-channel clarity": {
              "weight": 0.2
            }
          }
        },
        {
          "name": "Utilization management and access friction",
          "keyQuestions": [
            "What utilization management is most commonly applied (prior auth, step therapy, quantity limits, BMI thresholds, renewal criteria)?",
            "What are the most restrictive vs least restrictive requirements?",
            "Are there distinct rules for obesity vs diabetes indications or maintenance use?",
            "How often do policies require lifestyle program participation or specialist prescribing?"
          ],
          "sourceClasses": [
            "Coverage policies and PA criteria documents",
            "Formulary exception criteria",
            "Plan/provider manuals",
            "PBM UM criteria",
            "Provider-facing educational materials"
          ],
          "optionalEvidence": [
            "Member complaint themes",
            "Provider forum discussions",
            "Appeals-related anecdotes"
          ],
          "requiredEvidence": [
            "Explicit UM criteria from representative plans/PBMs",
            "Renewal and continuation requirements"
          ],
          "analogScoringDimensions": {
            "UM burden": {
              "weight": 0.4
            },
            "Renewal stringency": {
              "weight": 0.2
            },
            "Clinical specificity": {
              "weight": 0.2
            },
            "Operational complexity": {
              "weight": 0.2
            }
          }
        },
        {
          "name": "Evidence expectations and payer value assessment",
          "keyQuestions": [
            "What evidence do payers prioritize for coverage and tiering decisions?",
            "How do they weigh weight-loss efficacy vs hard outcomes, safety, durability, and real-world adherence?",
            "What economic evidence is persuasive: budget impact, cost offsets, productivity, reduced comorbidity burden?",
            "What evidence gaps do payers cite as reasons for restriction?"
          ],
          "sourceClasses": [
            "Payer medical policy rationale text",
            "Health plan PBM value frameworks",
            "HTA / ICER-style assessments relevant to obesity",
            "Payer conference presentations and interviews",
            "Published payer-perspective articles and reviews"
          ],
          "optionalEvidence": [
            "Academic HTA and budget-impact models",
            "Employer or consultant viewpoints",
            "Real-world evidence studies"
          ],
          "requiredEvidence": [
            "Direct payer rationale for inclusion/exclusion/tiering",
            "Any stated evidence thresholds or decision factors"
          ],
          "analogScoringDimensions": {
            "Evidence rigor demanded": {
              "weight": 0.3
            },
            "Value definition maturity": {
              "weight": 0.25
            },
            "Economic evidence sensitivity": {
              "weight": 0.2
            },
            "Importance of long-term outcomes": {
              "weight": 0.25
            }
          }
        },
        {
          "name": "Employer and purchaser influence",
          "keyQuestions": [
            "How do employer-sponsored plans affect access to obesity medications?",
            "Are employers pushing for broader coverage, exclusions, or carve-outs?",
            "What role do benefit consultants and PBMs play in shaping obesity coverage?",
            "Do employers prioritize productivity and retention outcomes or near-term cost containment?"
          ],
          "sourceClasses": [
            "Employer benefit surveys",
            "Consultant and broker publications",
            "PBM/employer roundtables",
            "Conference panels",
            "Benefits strategy articles"
          ],
          "optionalEvidence": [
            "Large-employer case studies",
            "Survey trend data by employer size/industry"
          ],
          "requiredEvidence": [
            "Current employer sentiment on obesity drug coverage",
            "At least a few examples of employer-driven coverage decisions"
          ],
          "analogScoringDimensions": {
            "Cost sensitivity": {
              "weight": 0.25
            },
            "Persistence of coverage": {
              "weight": 0.15
            },
            "Employer demand strength": {
              "weight": 0.35
            },
            "Influence on plan design": {
              "weight": 0.25
            }
          }
        },
        {
          "name": "Competitor positioning and contracting opportunities",
          "keyQuestions": [
            "How are manufacturers positioning payer value propositions for anti-obesity therapies?",
            "What claims are emphasized: outcomes, adherence support, cardiometabolic benefit, convenience, patient support?",
            "Are innovative contracting models emerging (outcomes-based, rebate, risk-sharing, guarantees)?",
            "Which unmet payer needs create differentiation opportunities?"
          ],
          "sourceClasses": [
            "Manufacturer payer decks and press releases",
            "Conference presentations and investor materials",
            "KOL/advisor commentary",
            "Payer-facing partnership announcements",
            "Deal announcements and contract case studies"
          ],
          "optionalEvidence": [
            "Speculative pipeline positioning",
            "Consumer marketing claims unless tied to payer narrative"
          ],
          "requiredEvidence": [
            "Payer-facing value propositions for key competitors",
            "Any documented contracting model examples"
          ],
          "analogScoringDimensions": {
            "Credibility of claims": {
              "weight": 0.2
            },
            "Contracting innovation": {
              "weight": 0.25
            },
            "Differentiation clarity": {
              "weight": 0.3
            },
            "Alignment to payer needs": {
              "weight": 0.25
            }
          }
        }
      ],
      "stopConditions": [
        "Sufficient to characterize coverage and UM for a representative set of major national commercial plans and Medicare Advantage plans, plus 2-4 influential PBMs",
        "At least one current policy or policy summary captured for each priority payer segment",
        "Recurring evidence themes identified with no major unresolved contradiction in coverage direction",
        "Enough sources collected to support a defensible synthesis of payer value criteria and employer influence",
        "Stop early if additional sources are only duplicative and do not change the coverage/access conclusion"
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"researchPlan\":{\"workstreams\":[{\"name\":\"Coverage landscape by payer segment\",\"keyQuestions\":[\"Which major U.S. commercial plans and Medicare Advantage plans cover anti-obesity medications today?\",\"What products are covered, excluded, or access-limited by plan and benefit channel?\",\"How do pharmacy vs medical benefit policies differ?\",\"What recent coverage changes occurred in the last 12–18 months?\"],\"sourceClasses\":[\"Payer formulary and medical/pharmacy policy documents\",\"PBM formulary and coverage tools\",\"Plan websites and member benefits pages\",\"Policy update notices / archives\",\"Secondary trackers and payer policy databases\"],\"requiredEvidence\":[\"Current public coverage/policy documents for priority national and regional plans\",\"Evidence of recent policy changes or launch/refresh dates\"],\"optionalEvidence\":[\"State-by-state plan comparisons\",\"Historical policy evolution beyond 18 months\",\"Benefit design details from employer summaries\"],\"analogScoringDimensions\":{\"Coverage breadth\":{\"weight\":0.35},\"Access restrictiveness\":{\"weight\":0.25},\"Recent policy momentum\":{\"weight\":0.2},\"Benefit-channel clarity\":{\"weight\":0.2}}},{\"name\":\"Utilization management and access friction\",\"keyQuestions\":[\"What utilization management is most commonly applied (prior auth, step therapy, quantity limits, BMI thresholds, renewal criteria)?\",\"What are the most restrictive vs least restrictive requirements?\",\"Are there distinct rules for obesity vs diabetes indications or maintenance use?\",\"How often do policies require lifestyle program participation or specialist prescribing?\"],\"sourceClasses\":[\"Coverage policies and PA criteria documents\",\"Formulary exception criteria\",\"Plan/provider manuals\",\"PBM UM criteria\",\"Provider-facing educational materials\"],\"requiredEvidence\":[\"Explicit UM criteria from representative plans/PBMs\",\"Renewal and continuation requirements\"],\"optionalEvidence\":[\"Member complaint themes\",\"Provider forum discussions\",\"Appeals-related anecdotes\"],\"analogScoringDimensions\":{\"UM burden\":{\"weight\":0.4},\"Clinical specificity\":{\"weight\":0.2},\"Renewal stringency\":{\"weight\":0.2},\"Operational complexity\":{\"weight\":0.2}}},{\"name\":\"Evidence expectations and payer value assessment\",\"keyQuestions\":[\"What evidence do payers prioritize for coverage and tiering decisions?\",\"How do they weigh weight-loss efficacy vs hard outcomes, safety, durability, and real-world adherence?\",\"What economic evidence is persuasive: budget impact, cost offsets, productivity, reduced comorbidity burden?\",\"What evidence gaps do payers cite as reasons for restriction?\"],\"sourceClasses\":[\"Payer medical policy rationale text\",\"Health plan PBM value frameworks\",\"HTA / ICER-style assessments relevant to obesity\",\"Payer conference presentations and interviews\",\"Published payer-perspective articles and reviews\"],\"requiredEvidence\":[\"Direct payer rationale for inclusion/exclusion/tiering\",\"Any stated evidence thresholds or decision factors\"],\"optionalEvidence\":[\"Academic HTA and budget-impact models\",\"Employer or consultant viewpoints\",\"Real-world evidence studies\"],\"analogScoringDimensions\":{\"Evidence rigor demanded\":{\"weight\":0.3},\"Value definition maturity\":{\"weight\":0.25},\"Importance of long-term outcomes\":{\"weight\":0.25},\"Economic evidence sensitivity\":{\"weight\":0.2}}},{\"name\":\"Employer and purchaser influence\",\"keyQuestions\":[\"How do employer-sponsored plans affect access to obesity medications?\",\"Are employers pushing for broader coverage, exclusions, or carve-outs?\",\"What role do benefit consultants and PBMs play in shaping obesity coverage?\",\"Do employers prioritize productivity and retention outcomes or near-term cost containment?\"],\"sourceClasses\":[\"Employer benefit surveys\",\"Consultant and broker publications\",\"PBM/employer roundtables\",\"Conference panels\",\"Benefits strategy articles\"],\"requiredEvidence\":[\"Current employer sentiment on obesity drug coverage\",\"At least a few examples of employer-driven coverage decisions\"],\"optionalEvidence\":[\"Large-employer case studies\",\"Survey trend data by employer size/industry\"],\"analogScoringDimensions\":{\"Employer demand strength\":{\"weight\":0.35},\"Cost sensitivity\":{\"weight\":0.25},\"Influence on plan design\":{\"weight\":0.25},\"Persistence of coverage\":{\"weight\":0.15}}},{\"name\":\"Competitor positioning and contracting opportunities\",\"keyQuestions\":[\"How are manufacturers positioning payer value propositions for anti-obesity therapies?\",\"What claims are emphasized: outcomes, adherence support, cardiometabolic benefit, convenience, patient support?\",\"Are innovative contracting models emerging (outcomes-based, rebate, risk-sharing, guarantees)?\",\"Which unmet payer needs create differentiation opportunities?\"],\"sourceClasses\":[\"Manufacturer payer decks and press releases\",\"Conference presentations and investor materials\",\"KOL/advisor commentary\",\"Payer-facing partnership announcements\",\"Deal announcements and contract case studies\"],\"requiredEvidence\":[\"Payer-facing value propositions for key competitors\",\"Any documented contracting model examples\"],\"optionalEvidence\":[\"Speculative pipeline positioning\",\"Consumer marketing claims unless tied to payer narrative\"],\"analogScoringDimensions\":{\"Differentiation clarity\":{\"weight\":0.3},\"Contracting innovation\":{\"weight\":0.25},\"Alignment to payer needs\":{\"weight\":0.25},\"Credibility of claims\":{\"weight\":0.2}}}],\"stopConditions\":[\"Sufficient to characterize coverage and UM for a representative set of major national commercial plans and Medicare Advantage plans, plus 2-4 influential PBMs\",\"At least one current policy or policy summary captured for each priority payer segment\",\"Recurring evidence themes identified with no major unresolved contradiction in coverage direction\",\"Enough sources collected to support a defensible synthesis of payer value criteria and employer influence\",\"Stop early if additional sources are only duplicative and do not change the coverage/access conclusion\"],\"knownRisks\":[\"Public policies may lag actual adjudication or employer-specific carve-outs\",\"Plan documents may omit rationale, requiring inference from secondary sources\",\"Some Medicare Advantage and employer decisions may be opaque or non-public\",\"Direct payer quotes may be sparse, reducing specificity of value assessment\",\"Rapid policy changes may outpace the source window\",\"Competitor claims may be promotional and not reflect payer adoption\",\"Pharmacy-benefit coverage may be easier to document than medical-benefit exceptions\"]}}",
  "providerResponseId": "resp_0e9d9f73a62369a7006a05f43e41e481a0a82affda10db4336"
}

{
  "output": {
    "researchSources": {
      "sources": [
        {
          "title": "UnitedHealthcare Pharmacy weight-loss prior authorization notice",
          "evidence": "Program 2026 P 1114-20 covers Wegovy, Wegovy tablet, Zepbound, Saxenda, Qsymia, Contrave, orlistat/Xenical, and others; effective 2026-05-01. The notice indicates prior authorization/notification for plans with weight-loss/appetite-suppression medication coverage and lists repeated P&T approval updates through 2026.",
          "publisher": "UnitedHealthcare",
          "sourceType": "payer_policy",
          "publishedDate": "2026-04-24",
          "urlOrReference": "https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf"
        },
        {
          "title": "Aetna Zepbound Exception clinical policy bulletin",
          "evidence": "Commercial pharmacy policy for Zepbound states it is for reducing excess body weight and maintaining weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition; notes medications on the plan may still require clinical prior authorization review.",
          "publisher": "Aetna",
          "sourceType": "payer_policy",
          "publishedDate": "2025-06-01",
          "urlOrReference": "https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_Exception_%28ACCF%2C_ACF%2C_ACFC%2C_SCCF%2C_SF%2C_SFC%2C_VF%2C_VFC%29_6981-A_P04-2025.html"
        },
        {
          "title": "Aetna Medicare HIDE (HMO D-SNP) Medicaid Weight Loss Prior Authorization Criteria",
          "evidence": "Current obesity/weight-loss PA criteria for multiple agents including Wegovy, Zepbound, Saxenda, Xenical, phentermine products, and phentermine/topiramate. Shows explicit initial criteria (age, BMI, comorbidities) and states 'No updates made since 12/12/2025.'",
          "publisher": "Aetna",
          "sourceType": "payer_policy",
          "publishedDate": "2025-12-12",
          "urlOrReference": "https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf"
        }
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"researchSources\":{\"sources\":[{\"urlOrReference\":\"https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf\",\"title\":\"UnitedHealthcare Pharmacy weight-loss prior authorization notice\",\"publisher\":\"UnitedHealthcare\",\"publishedDate\":\"2026-04-24\",\"evidence\":\"Program 2026 P 1114-20 covers Wegovy, Wegovy tablet, Zepbound, Saxenda, Qsymia, Contrave, orlistat/Xenical, and others; effective 2026-05-01. The notice indicates prior authorization/notification for plans with weight-loss/appetite-suppression medication coverage and lists repeated P&T approval updates through 2026.\",\"sourceType\":\"payer_policy\"},{\"urlOrReference\":\"https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_Exception_%28ACCF%2C_ACF%2C_ACFC%2C_SCCF%2C_SF%2C_SFC%2C_VF%2C_VFC%29_6981-A_P04-2025.html\",\"title\":\"Aetna Zepbound Exception clinical policy bulletin\",\"publisher\":\"Aetna\",\"publishedDate\":\"2025-06-01\",\"evidence\":\"Commercial pharmacy policy for Zepbound states it is for reducing excess body weight and maintaining weight reduction long term in adults with obesity or overweight with at least one weight-related comorbid condition; notes medications on the plan may still require clinical prior authorization review.\",\"sourceType\":\"payer_policy\"},{\"urlOrReference\":\"https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf\",\"title\":\"Aetna Medicare HIDE (HMO D-SNP) Medicaid Weight Loss Prior Authorization Criteria\",\"publisher\":\"Aetna\",\"publishedDate\":\"2025-12-12\",\"evidence\":\"Current obesity/weight-loss PA criteria for multiple agents including Wegovy, Zepbound, Saxenda, Xenical, phentermine products, and phentermine/topiramate. Shows explicit initial criteria (age, BMI, comorbidities) and states 'No updates made since 12/12/2025.'\",\"sourceType\":\"payer_policy\"}]}}",
  "providerResponseId": "resp_03cec217dd2e444d006a05f4554b2c8191b6ac0ad96d67ff6f"
}

{
  "output": {
    "marketScan": {
      "Coverage Landscape": {
        "Summary": "Major U.S. commercial and Medicare Advantage plans generally provide pharmacy‐benefit coverage for branded anti‐obesity medications under prior authorization (PA) or exception‐based programs. UnitedHealthcare’s national commercial plans cover a comprehensive portfolio—including phentermine products, Contrave, Imcivree, Qsymia, Saxenda, Wegovy (injection and tablet), Zepbound, Xenical, and others—under Program 2026 P 1114-20, effective May 1, 2026. Coverage criteria include FDA‐approved obesity/weight‐loss indications, cardiovascular risk reduction, MASH therapy, and adjunctive lifestyle modification, with explicit BMI thresholds and age limits for initial and renewal approvals ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf)). Aetna’s non-Medicare formulary places Wegovy as the primary alternative and Mounjaro (tirzepatide) as the secondary alternative under its Zepbound Exception policy (effective July 1, 2025), requiring prescribers to document intolerance or contraindication to Wegovy before approving Zepbound ([aetna.com](https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_Exception_%28ACCF%2C_ACF%2C_ACFC%2C_SCCF%2C_SF%2C_SFC%2C_VF%2C_VFC%29_6981-A_P04-2025.html)). In its Medicare HIDE (HMO D-SNP) plan, Aetna similarly covers GLP-1 and non-GLP-1 weight-loss agents (e.g., phentermine, diethylpropion, orlistat) via clinical PA criteria that specify age (≥18 years or pediatric BMI percentiles), single‐agent use, BMI ≥30 kg/m2 (or ≥27 kg/m2 with comorbidities), and no concurrent weight‐loss medications; this policy has been stable since December 12, 2025 ([aetna.com](https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf?utm_source=openai))."
      },
      "Overall Assumptions": [
        "Analysis centers on pharmacy‐benefit policies for branded obesity pharmacotherapies from UHC and Aetna; other national/regional payers (e.g., Cigna, Humana) likely follow comparable PA and BMI/comorbidity requirements.",
        "Publicly posted PA criteria reflect broad coverage approach but may not capture plan‐specific carve-outs or negotiated overrides.",
        "Employer‐driven exceptions and innovative contracting models are assumed based on industry trends; granular case examples are largely non-public.",
        "Value assessment insights are inferred from policy rationales referencing guideline bodies and indication expansions rather than explicit economic thresholds."
      ],
      "Utilization Management": {
        "Common Requirements": "All reviewed plans mandate prior authorization with a combination of clinical and operational criteria. UHC requires: (1) documented indication (appetite suppression, weight loss, CV risk reduction in established CVD, or MASH/NASH therapy); (2) age and BMI thresholds (≥12 years for certain agents, ≥16 years for others; BMI ≥30 kg/m² or ≥27 kg/m² with comorbidity); (3) evidence of lifestyle program participation; and (4) reauthorization weight‐loss milestones (3–5% ∆ baseline weight depending on agent), with renewal intervals ranging from 3 to 6 months for initial approval and up to 12 months for reauthorization ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf)). Aetna HIDE’s clinical PA requires single‐agent use, age and BMI criteria (including pediatric percentiles and ≥18 years adult thresholds), and documentation of comorbidities (diabetes, OSA, hypertension, dyslipidemia) for initial and renewal approvals ([aetna.com](https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf?utm_source=openai)). Under Aetna’s Zepbound Exception, prescribers must first attempt Wegovy; only upon documented intolerance, contraindication, or inadequate response may Zepbound be approved ([aetna.com](https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_Exception_%28ACCF%2C_ACF%2C_ACFC%2C_SCCF%2C_SF%2C_SFC%2C_VF%2C_VFC%29_6981-A_P04-2025.html))."
      },
      "Evidence and Value Assessment": {
        "Economic Value": "Neither UHC nor Aetna detail explicit budget‐impact thresholds in public policy documents, but both reference national guideline recommendations (e.g., American Association of Clinical Endocrinologists) to justify coverage breadth—suggesting payers seek evidence of comorbidity reduction and downstream cost offsets ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf)). Aetna’s HIDE criteria list weight-related comorbidities (diabetes, OSA, hypertension, dyslipidemia) as prerequisites for approval, indicating sensitivity to potential healthcare‐cost avoidance associated with these conditions ([aetna.com](https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf?utm_source=openai)).",
        "Clinical Efficacy": "Payers prioritize FDA‐approved indications and guideline‐endorsed outcomes. UHC explicitly covers semaglutide and tirzepatide for MACE risk reduction in patients with established cardiovascular disease—aligning with evidence from CVOTs—and for MASH with moderate‐to‐advanced fibrosis, citing both indication and positive clinical response (e.g., fibrosis improvement) ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf)). Aetna’s Zepbound policy emphasizes long-term weight‐loss maintenance and treatment of OSA per the FDA insert; it relies on prescriber attestation of dietary/exercise adjunctive use and GLP-1 coadministration avoidance ([aetna.com](https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_Exception_%28ACCF%2C_ACF%2C_ACFC%2C_SCCF%2C_SF%2C_SFC%2C_VF%2C_VFC%29_6981-A_P04-2025.html))."
      },
      "Employer Influence and Unmet Needs": {
        "Assumptions": [
          "Direct employer‐level coverage carve-outs are not publicly available; we assume large, self-insured employers largely follow PBM-driven formulary design, with pockets of aggressive coverage for GLP-1s in employers prioritizing productivity and retention.",
          "Benefit consultants likely emphasize short-term cost containment—evident in tiered formulary placement and PA stringency—while employers requesting broader coverage may leverage outcomes-based contracting to mitigate budget impact."
        ],
        "Key Unmet Needs": [
          "Real-world adherence data tied to long-term healthcare utilization offsets.",
          "Robust economic models demonstrating ROI over 2–5 years.",
          "Simplified renewal criteria to reduce administrative burden.",
          "Integrated coverage pathways combining lifestyle programs and pharmacotherapy."
        ]
      },
      "Long‐Term Outcomes & Real‐World Concerns": {
        "Payer Focus": "Plans couple coverage with reauthorization criteria based on weight‐loss percentiles (3–5%), reflecting concerns about durability and adherence; failure to meet thresholds may interrupt therapy ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf)). UHC’s renewal rules require documented clinical response (e.g., fibrosis stabilization for Wegovy in MASH) or weight‐loss targets, underscoring payer emphasis on sustained outcomes ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf))."
      },
      "Competitor Positioning & Contracting Opportunities": {
        "Assumptions": [
          "Novo Nordisk’s payer value messaging for Wegovy likely highlights superior ≥15% weight‐loss from SURMOUNT trials and positive CVOT results.",
          "Lilly’s Zepbound propositions emphasize OSA indication and potential for greater glycemic improvements in T2D subpopulations.",
          "Emerging outcomes-based contracts may link rebates or guarantees to CV event reduction or weight‐loss milestones, but documented payer agreements remain scarce in the public domain."
        ]
      }
    }
  },
  "status": "completed",
  "rawProviderText": "{\"marketScan\":{\"Coverage Landscape\":{\"Summary\":\"Major U.S. commercial and Medicare Advantage plans generally provide pharmacy‐benefit coverage for branded anti‐obesity medications under prior authorization (PA) or exception‐based programs. UnitedHealthcare’s national commercial plans cover a comprehensive portfolio—including phentermine products, Contrave, Imcivree, Qsymia, Saxenda, Wegovy (injection and tablet), Zepbound, Xenical, and others—under Program 2026 P 1114-20, effective May 1, 2026. Coverage criteria include FDA‐approved obesity/weight‐loss indications, cardiovascular risk reduction, MASH therapy, and adjunctive lifestyle modification, with explicit BMI thresholds and age limits for initial and renewal approvals ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf)). Aetna’s non-Medicare formulary places Wegovy as the primary alternative and Mounjaro (tirzepatide) as the secondary alternative under its Zepbound Exception policy (effective July 1, 2025), requiring prescribers to document intolerance or contraindication to Wegovy before approving Zepbound ([aetna.com](https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_Exception_%28ACCF%2C_ACF%2C_ACFC%2C_SCCF%2C_SF%2C_SFC%2C_VF%2C_VFC%29_6981-A_P04-2025.html)). In its Medicare HIDE (HMO D-SNP) plan, Aetna similarly covers GLP-1 and non-GLP-1 weight-loss agents (e.g., phentermine, diethylpropion, orlistat) via clinical PA criteria that specify age (≥18 years or pediatric BMI percentiles), single‐agent use, BMI ≥30 kg/m2 (or ≥27 kg/m2 with comorbidities), and no concurrent weight‐loss medications; this policy has been stable since December 12, 2025 ([aetna.com](https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf?utm_source=openai)).\"},\"Utilization Management\":{\"Common Requirements\":\"All reviewed plans mandate prior authorization with a combination of clinical and operational criteria. UHC requires: (1) documented indication (appetite suppression, weight loss, CV risk reduction in established CVD, or MASH/NASH therapy); (2) age and BMI thresholds (≥12 years for certain agents, ≥16 years for others; BMI ≥30 kg/m² or ≥27 kg/m² with comorbidity); (3) evidence of lifestyle program participation; and (4) reauthorization weight‐loss milestones (3–5% ∆ baseline weight depending on agent), with renewal intervals ranging from 3 to 6 months for initial approval and up to 12 months for reauthorization ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf)). Aetna HIDE’s clinical PA requires single‐agent use, age and BMI criteria (including pediatric percentiles and ≥18 years adult thresholds), and documentation of comorbidities (diabetes, OSA, hypertension, dyslipidemia) for initial and renewal approvals ([aetna.com](https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf?utm_source=openai)). Under Aetna’s Zepbound Exception, prescribers must first attempt Wegovy; only upon documented intolerance, contraindication, or inadequate response may Zepbound be approved ([aetna.com](https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_Exception_%28ACCF%2C_ACF%2C_ACFC%2C_SCCF%2C_SF%2C_SFC%2C_VF%2C_VFC%29_6981-A_P04-2025.html)).\"},\"Evidence and Value Assessment\":{\"Clinical Efficacy\":\"Payers prioritize FDA‐approved indications and guideline‐endorsed outcomes. UHC explicitly covers semaglutide and tirzepatide for MACE risk reduction in patients with established cardiovascular disease—aligning with evidence from CVOTs—and for MASH with moderate‐to‐advanced fibrosis, citing both indication and positive clinical response (e.g., fibrosis improvement) ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf)). Aetna’s Zepbound policy emphasizes long-term weight‐loss maintenance and treatment of OSA per the FDA insert; it relies on prescriber attestation of dietary/exercise adjunctive use and GLP-1 coadministration avoidance ([aetna.com](https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_Exception_%28ACCF%2C_ACF%2C_ACFC%2C_SCCF%2C_SF%2C_SFC%2C_VF%2C_VFC%29_6981-A_P04-2025.html)).\",\"Economic Value\":\"Neither UHC nor Aetna detail explicit budget‐impact thresholds in public policy documents, but both reference national guideline recommendations (e.g., American Association of Clinical Endocrinologists) to justify coverage breadth—suggesting payers seek evidence of comorbidity reduction and downstream cost offsets ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf)). Aetna’s HIDE criteria list weight-related comorbidities (diabetes, OSA, hypertension, dyslipidemia) as prerequisites for approval, indicating sensitivity to potential healthcare‐cost avoidance associated with these conditions ([aetna.com](https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf?utm_source=openai)).\"},\"Long‐Term Outcomes & Real‐World Concerns\":{\"Payer Focus\":\"Plans couple coverage with reauthorization criteria based on weight‐loss percentiles (3–5%), reflecting concerns about durability and adherence; failure to meet thresholds may interrupt therapy ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf)). UHC’s renewal rules require documented clinical response (e.g., fibrosis stabilization for Wegovy in MASH) or weight‐loss targets, underscoring payer emphasis on sustained outcomes ([uhcprovider.com](https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf)).\"},\"Employer Influence and Unmet Needs\":{\"Assumptions\":[\"Direct employer‐level coverage carve-outs are not publicly available; we assume large, self-insured employers largely follow PBM-driven formulary design, with pockets of aggressive coverage for GLP-1s in employers prioritizing productivity and retention.\",\"Benefit consultants likely emphasize short-term cost containment—evident in tiered formulary placement and PA stringency—while employers requesting broader coverage may leverage outcomes-based contracting to mitigate budget impact.\"],\"Key Unmet Needs\":[\"Real-world adherence data tied to long-term healthcare utilization offsets.\",\"Robust economic models demonstrating ROI over 2–5 years.\",\"Simplified renewal criteria to reduce administrative burden.\",\"Integrated coverage pathways combining lifestyle programs and pharmacotherapy.\"]},\"Competitor Positioning & Contracting Opportunities\":{\"Assumptions\":[\"Novo Nordisk’s payer value messaging for Wegovy likely highlights superior ≥15% weight‐loss from SURMOUNT trials and positive CVOT results.\",\"Lilly’s Zepbound propositions emphasize OSA indication and potential for greater glycemic improvements in T2D subpopulations.\",\"Emerging outcomes-based contracts may link rebates or guarantees to CV event reduction or weight‐loss milestones, but documented payer agreements remain scarce in the public domain.\"]},\"Overall Assumptions\":[\"Analysis centers on pharmacy‐benefit policies for branded obesity pharmacotherapies from UHC and Aetna; other national/regional payers (e.g., Cigna, Humana) likely follow comparable PA and BMI/comorbidity requirements.\",\"Publicly posted PA criteria reflect broad coverage approach but may not capture plan‐specific carve-outs or negotiated overrides.\",\"Employer‐driven exceptions and innovative contracting models are assumed based on industry trends; granular case examples are largely non-public.\",\"Value assessment insights are inferred from policy rationales referencing guideline bodies and indication expansions rather than explicit economic thresholds.\"]}}",
  "providerResponseId": "resp_0f6d01a078873657006a05f45ba49481929dd7a6b6d6530073"
}

{
  "output": {
    "analogCandidates": {
      "UHC_Aetna_PayerPolicy_Analog": {
        "scores": {
          "weighted_score": 4.55,
          "coverage_breadth": 4,
          "access_restrictiveness": 5,
          "recent_policy_momentum": 5,
          "benefit_channel_clarity": 4
        },
        "selected": true,
        "keyDifferences": [
          "Narrow source base: only two payers plus one Medicare HIDE line, not a broad market sample",
          "Public policy docs may not reflect actual adjudication or employer carve-outs",
          "Little direct payer rationale or quote-level evidence",
          "Limited visibility into PBM, employer, and medical-benefit exceptions"
        ],
        "keySimilarities": [
          "Same therapeutic area (anti-obesity pharmacotherapies)",
          "Same payer decision context (commercial and Medicare Advantage)",
          "Contains explicit PA/renewal criteria and coverage positioning",
          "Includes recent policy updates within the target window",
          "Shows evidence signals payers prioritize (BMI/comorbidity thresholds, response milestones, lifestyle requirements)"
        ],
        "selection_rationale": "Strong structural fit and high evidentiary quality; selected as a core analog for coverage/UM benchmarking, but not sufficient alone for market-wide conclusions.",
        "whyStructurallyRelevant": "Directly matches the target problem: current U.S. payer coverage, UM, and evidence logic for anti-obesity drugs, with concrete policy documents and recent updates."
      },
      "PBM_Formulary_PriorAuth_Analog": {
        "scores": {
          "weighted_score": 3.7,
          "coverage_breadth": 3,
          "access_restrictiveness": 4,
          "recent_policy_momentum": 4,
          "benefit_channel_clarity": 4
        },
        "selected": true,
        "keyDifferences": [
          "Evidence here is inferential rather than directly observed across multiple PBMs",
          "Lacks documented comparator breadth versus named plan policies",
          "No strong proof of long-term outcomes or value framework prioritization",
          "May overgeneralize from pharmacy-benefit rules to the entire market"
        ],
        "keySimilarities": [
          "Same access mechanism (PA, exception pathways, step edits)",
          "Same payer-adjacent decision layer affecting commercial access",
          "Useful for understanding operational friction and channel-specific rules",
          "Relevant to employer-sponsored plans that rely on PBMs"
        ],
        "selection_rationale": "Useful supporting analog for UM design and formulary mechanics, though weaker on breadth and direct evidence than payer policy documents.",
        "whyStructurallyRelevant": "PBM-driven formulary and PA programs are central to obesity access management, and this analog captures how benefit managers operationalize restrictions and renewals."
      },
      "Employer_Coverage_Influence_Analog": {
        "scores": {
          "weighted_score": 2.25,
          "coverage_breadth": 2,
          "access_restrictiveness": 3,
          "recent_policy_momentum": 2,
          "benefit_channel_clarity": 2
        },
        "selected": false,
        "keyDifferences": [
          "Employer sentiment and decisions are mostly assumed, not directly evidenced",
          "Sparse concrete case examples of employer-driven obesity coverage",
          "Influence is indirect unless tied to specific plan/PBM arrangements",
          "Not a clean analog for formal payer medical policy criteria"
        ],
        "keySimilarities": [
          "Same decision tension between access and affordability",
          "Same influence on tiering, exclusions, and carve-outs",
          "Relevant to productivity/retention vs short-term cost tradeoffs",
          "Can explain heterogeneity beyond published payer policies"
        ],
        "selection_rationale": "Structurally relevant but evidence-poor and too inferential; reject as a primary analog unless supported by stronger employer-specific sources.",
        "whyStructurallyRelevant": "Employer-sponsored coverage is a major driver of obesity drug access and cost containment, so employer benefit design is a relevant structural counterpart to payer policy decisions."
      },
      "Competitor_Value_Proposition_Analog": {
        "scores": {
          "weighted_score": 1.55,
          "coverage_breadth": 2,
          "access_restrictiveness": 1,
          "recent_policy_momentum": 2,
          "benefit_channel_clarity": 1
        },
        "selected": false,
        "keyDifferences": [
          "Current source set lacks direct manufacturer decks or documented contracts",
          "Much of the competitor section is speculative, not source-grounded",
          "Does not directly show payer acceptance or formulary impact",
          "Can become flashy but structurally weak without concrete deal evidence"
        ],
        "keySimilarities": [
          "Focuses on payer-facing evidence claims and value narratives",
          "Relevant to contracting models and differentiation opportunities",
          "Connects clinical outcomes to access decisions",
          "Captures how companies frame unmet payer needs"
        ],
        "selection_rationale": "Reject as a primary analog because the evidence base is too thin and mostly inferential; useful only after direct manufacturer or deal sources are added.",
        "whyStructurallyRelevant": "The question includes how competitors position value to payers, so manufacturer payer messaging and contracting attempts are a natural analog for assessing access differentiation."
      }
    }
  },
  "status": "completed",
  "rawProviderText": "{\"analogCandidates\":{\"UHC_Aetna_PayerPolicy_Analog\":{\"whyStructurallyRelevant\":\"Directly matches the target problem: current U.S. payer coverage, UM, and evidence logic for anti-obesity drugs, with concrete policy documents and recent updates.\",\"keySimilarities\":[\"Same therapeutic area (anti-obesity pharmacotherapies)\",\"Same payer decision context (commercial and Medicare Advantage)\",\"Contains explicit PA/renewal criteria and coverage positioning\",\"Includes recent policy updates within the target window\",\"Shows evidence signals payers prioritize (BMI/comorbidity thresholds, response milestones, lifestyle requirements)\"],\"keyDifferences\":[\"Narrow source base: only two payers plus one Medicare HIDE line, not a broad market sample\",\"Public policy docs may not reflect actual adjudication or employer carve-outs\",\"Little direct payer rationale or quote-level evidence\",\"Limited visibility into PBM, employer, and medical-benefit exceptions\"],\"scores\":{\"coverage_breadth\":4,\"access_restrictiveness\":5,\"recent_policy_momentum\":5,\"benefit_channel_clarity\":4,\"weighted_score\":4.55},\"selected\":true,\"selection_rationale\":\"Strong structural fit and high evidentiary quality; selected as a core analog for coverage/UM benchmarking, but not sufficient alone for market-wide conclusions.\"},\"PBM_Formulary_PriorAuth_Analog\":{\"whyStructurallyRelevant\":\"PBM-driven formulary and PA programs are central to obesity access management, and this analog captures how benefit managers operationalize restrictions and renewals.\",\"keySimilarities\":[\"Same access mechanism (PA, exception pathways, step edits)\",\"Same payer-adjacent decision layer affecting commercial access\",\"Useful for understanding operational friction and channel-specific rules\",\"Relevant to employer-sponsored plans that rely on PBMs\"],\"keyDifferences\":[\"Evidence here is inferential rather than directly observed across multiple PBMs\",\"Lacks documented comparator breadth versus named plan policies\",\"No strong proof of long-term outcomes or value framework prioritization\",\"May overgeneralize from pharmacy-benefit rules to the entire market\"],\"scores\":{\"coverage_breadth\":3,\"access_restrictiveness\":4,\"recent_policy_momentum\":4,\"benefit_channel_clarity\":4,\"weighted_score\":3.7},\"selected\":true,\"selection_rationale\":\"Useful supporting analog for UM design and formulary mechanics, though weaker on breadth and direct evidence than payer policy documents.\"},\"Employer_Coverage_Influence_Analog\":{\"whyStructurallyRelevant\":\"Employer-sponsored coverage is a major driver of obesity drug access and cost containment, so employer benefit design is a relevant structural counterpart to payer policy decisions.\",\"keySimilarities\":[\"Same decision tension between access and affordability\",\"Same influence on tiering, exclusions, and carve-outs\",\"Relevant to productivity/retention vs short-term cost tradeoffs\",\"Can explain heterogeneity beyond published payer policies\"],\"keyDifferences\":[\"Employer sentiment and decisions are mostly assumed, not directly evidenced\",\"Sparse concrete case examples of employer-driven obesity coverage\",\"Influence is indirect unless tied to specific plan/PBM arrangements\",\"Not a clean analog for formal payer medical policy criteria\"],\"scores\":{\"coverage_breadth\":2,\"access_restrictiveness\":3,\"recent_policy_momentum\":2,\"benefit_channel_clarity\":2,\"weighted_score\":2.25},\"selected\":false,\"selection_rationale\":\"Structurally relevant but evidence-poor and too inferential; reject as a primary analog unless supported by stronger employer-specific sources.\"},\"Competitor_Value_Proposition_Analog\":{\"whyStructurallyRelevant\":\"The question includes how competitors position value to payers, so manufacturer payer messaging and contracting attempts are a natural analog for assessing access differentiation.\",\"keySimilarities\":[\"Focuses on payer-facing evidence claims and value narratives\",\"Relevant to contracting models and differentiation opportunities\",\"Connects clinical outcomes to access decisions\",\"Captures how companies frame unmet payer needs\"],\"keyDifferences\":[\"Current source set lacks direct manufacturer decks or documented contracts\",\"Much of the competitor section is speculative, not source-grounded\",\"Does not directly show payer acceptance or formulary impact\",\"Can become flashy but structurally weak without concrete deal evidence\"],\"scores\":{\"coverage_breadth\":2,\"access_restrictiveness\":1,\"recent_policy_momentum\":2,\"benefit_channel_clarity\":1,\"weighted_score\":1.55},\"selected\":false,\"selection_rationale\":\"Reject as a primary analog because the evidence base is too thin and mostly inferential; useful only after direct manufacturer or deal sources are added.\"}}}",
  "providerResponseId": "resp_010cf8ff3a838483006a05f482b0e8819da37f06385e594d4f"
}

{
  "output": {
    "analogAnalysis": {
      "caveats": [
        "Evidence base is thin and skewed toward publicly posted policy documents from only UHC and Aetna.",
        "Public criteria may overstate actual access because employer carve-outs, overrides, and adjudication rules are opaque.",
        "PBM and employer influence is real but not directly evidenced here; treat as directional, not conclusive.",
        "Competitor value-proposition insights are largely speculative and should not be used as primary conclusions."
      ],
      "bestNextEvidenceToDeRisk": [
        "Add 2-4 more national/regional payer policies plus 1-2 major PBM criteria sets.",
        "Collect payer quotes or conference commentary on long-term outcomes, adherence, and budget impact.",
        "Find employer-benefit survey data or consultant case examples tied to obesity drug coverage.",
        "Add manufacturer payer decks or documented contracting examples before drawing competitor conclusions."
      ],
      "primaryTransferablePatterns": [
        "Coverage decisions are driven by explicit PA/renewal gates, not broad open-access coverage.",
        "Payers prioritize objective thresholds: FDA indication, BMI/comorbidity, age, and response milestones.",
        "Continuation depends on measurable real-world response, signaling concern about adherence/durability.",
        "Pharmacy-benefit rules are more visible and operationally important than medical-benefit exceptions in public sources.",
        "Coverage expansion is tied to additional labeled indications with stronger long-term outcome evidence (e.g., CV risk reduction)."
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"analogAnalysis\":{\"primaryTransferablePatterns\":[\"Coverage decisions are driven by explicit PA/renewal gates, not broad open-access coverage.\",\"Payers prioritize objective thresholds: FDA indication, BMI/comorbidity, age, and response milestones.\",\"Continuation depends on measurable real-world response, signaling concern about adherence/durability.\",\"Pharmacy-benefit rules are more visible and operationally important than medical-benefit exceptions in public sources.\",\"Coverage expansion is tied to additional labeled indications with stronger long-term outcome evidence (e.g., CV risk reduction).\"],\"caveats\":[\"Evidence base is thin and skewed toward publicly posted policy documents from only UHC and Aetna.\",\"Public criteria may overstate actual access because employer carve-outs, overrides, and adjudication rules are opaque.\",\"PBM and employer influence is real but not directly evidenced here; treat as directional, not conclusive.\",\"Competitor value-proposition insights are largely speculative and should not be used as primary conclusions.\"],\"bestNextEvidenceToDeRisk\":[\"Add 2-4 more national/regional payer policies plus 1-2 major PBM criteria sets.\",\"Collect payer quotes or conference commentary on long-term outcomes, adherence, and budget impact.\",\"Find employer-benefit survey data or consultant case examples tied to obesity drug coverage.\",\"Add manufacturer payer decks or documented contracting examples before drawing competitor conclusions.\"]}}",
  "providerResponseId": "resp_0084cec39d0a753d006a05f48a60ac819eb563f703bd308e13"
}

{
  "output": {
    "evidence": {
      "sources": [
        {
          "id": "src_1",
          "title": "UnitedHealthcare Pharmacy weight-loss prior authorization notice",
          "publisher": "UnitedHealthcare",
          "sourceType": "payer_policy",
          "publishedDate": "2026-04-24",
          "urlOrReference": "https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf",
          "suspiciousFlags": [
            {
              "flag": "future_dated_source",
              "reason": "Published date is 2026-04-24 relative to current date context may be unusual but not inherently invalid."
            }
          ],
          "normalizedEvidence": [
            "UnitedHealthcare commercial plans use prior authorization/notification for weight-loss and appetite-suppression medications.",
            "Program 2026 P 1114-20 includes Wegovy, Wegovy tablet, Zepbound, Saxenda, Qsymia, Contrave, orlistat/Xenical, and others.",
            "Effective date noted as 2026-05-01.",
            "Policy updates were repeated through 2026."
          ]
        },
        {
          "id": "src_2",
          "title": "Aetna Zepbound Exception clinical policy bulletin",
          "publisher": "Aetna",
          "sourceType": "payer_policy",
          "publishedDate": "2025-06-01",
          "urlOrReference": "https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_Exception_%28ACCF%2C_ACF%2C_ACFC%2C_SCCF%2C_SF%2C_SFC%2C_VF%2C_VFC%29_6981-A_P04-2025.html",
          "suspiciousFlags": [],
          "normalizedEvidence": [
            "Aetna commercial pharmacy policy states Zepbound is for reducing excess body weight and maintaining weight reduction long term in adults with obesity or overweight plus at least one weight-related comorbid condition.",
            "Medications on the plan may still require clinical prior authorization review.",
            "Policy implies a step/exception pathway involving review before approval."
          ]
        },
        {
          "id": "src_3",
          "title": "Aetna Medicare HIDE (HMO D-SNP) Medicaid Weight Loss Prior Authorization Criteria",
          "publisher": "Aetna",
          "sourceType": "payer_policy",
          "publishedDate": "2025-12-12",
          "urlOrReference": "https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf",
          "suspiciousFlags": [
            {
              "flag": "potential_metadata_inconsistency",
              "reason": "Title says Medicare HIDE (HMO D-SNP) Medicaid Weight Loss Prior Authorization Criteria, which mixes Medicare and Medicaid terminology; source may still be valid but should be checked."
            }
          ],
          "normalizedEvidence": [
            "Aetna HIDE/D-SNP weight-loss prior authorization criteria cover multiple anti-obesity agents including Wegovy, Zepbound, Saxenda, Xenical, phentermine products, and phentermine/topiramate.",
            "Criteria include explicit initial requirements such as age, BMI, and comorbidities.",
            "Policy states no updates made since 2025-12-12."
          ]
        }
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"evidence\":{\"sources\":[{\"id\":\"src_1\",\"urlOrReference\":\"https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Notification-Weight-Loss.pdf\",\"title\":\"UnitedHealthcare Pharmacy weight-loss prior authorization notice\",\"publisher\":\"UnitedHealthcare\",\"publishedDate\":\"2026-04-24\",\"sourceType\":\"payer_policy\",\"normalizedEvidence\":[\"UnitedHealthcare commercial plans use prior authorization/notification for weight-loss and appetite-suppression medications.\",\"Program 2026 P 1114-20 includes Wegovy, Wegovy tablet, Zepbound, Saxenda, Qsymia, Contrave, orlistat/Xenical, and others.\",\"Effective date noted as 2026-05-01.\",\"Policy updates were repeated through 2026.\"],\"suspiciousFlags\":[{\"flag\":\"future_dated_source\",\"reason\":\"Published date is 2026-04-24 relative to current date context may be unusual but not inherently invalid.\"}]},{\"id\":\"src_2\",\"urlOrReference\":\"https://www.aetna.com/products/rxnonmedicare/data/2025/Zepbound_Exception_%28ACCF%2C_ACF%2C_ACFC%2C_SCCF%2C_SF%2C_SFC%2C_VF%2C_VFC%29_6981-A_P04-2025.html\",\"title\":\"Aetna Zepbound Exception clinical policy bulletin\",\"publisher\":\"Aetna\",\"publishedDate\":\"2025-06-01\",\"sourceType\":\"payer_policy\",\"normalizedEvidence\":[\"Aetna commercial pharmacy policy states Zepbound is for reducing excess body weight and maintaining weight reduction long term in adults with obesity or overweight plus at least one weight-related comorbid condition.\",\"Medications on the plan may still require clinical prior authorization review.\",\"Policy implies a step/exception pathway involving review before approval.\"],\"suspiciousFlags\":[]},{\"id\":\"src_3\",\"urlOrReference\":\"https://www.aetna.com/content/dam/aetna/medicaid/pdfs/formulary-updates/2026/Anti_Obesity_Agents_MI_HIDE_2026_updated_criteria122025_WF_approved_remediated.pdf\",\"title\":\"Aetna Medicare HIDE (HMO D-SNP) Medicaid Weight Loss Prior Authorization Criteria\",\"publisher\":\"Aetna\",\"publishedDate\":\"2025-12-12\",\"sourceType\":\"payer_policy\",\"normalizedEvidence\":[\"Aetna HIDE/D-SNP weight-loss prior authorization criteria cover multiple anti-obesity agents including Wegovy, Zepbound, Saxenda, Xenical, phentermine products, and phentermine/topiramate.\",\"Criteria include explicit initial requirements such as age, BMI, and comorbidities.\",\"Policy states no updates made since 2025-12-12.\"],\"suspiciousFlags\":[{\"flag\":\"potential_metadata_inconsistency\",\"reason\":\"Title says Medicare HIDE (HMO D-SNP) Medicaid Weight Loss Prior Authorization Criteria, which mixes Medicare and Medicaid terminology; source may still be valid but should be checked.\"}]}]}}",
  "providerResponseId": "resp_0319c1deb6bad978006a05f48eb14081979c74faac6784739d"
}

{
  "output": {
    "claimRecord": {
      "claims": [
        {
          "claim": "Major U.S. commercial and Medicare Advantage plans generally cover branded anti-obesity medications through pharmacy benefits, but typically only under prior authorization or exception-based programs.",
          "evidence": [
            "src_1",
            "src_2",
            "src_3"
          ],
          "confidence": "high"
        },
        {
          "claim": "UnitedHealthcare’s commercial policy covers a broad obesity-drug portfolio, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.",
          "evidence": [
            "src_1"
          ],
          "confidence": "high"
        },
        {
          "claim": "Payer access criteria commonly require FDA-labeled indication, BMI/age thresholds, lifestyle-program participation, and renewal-based weight-loss response milestones.",
          "evidence": [
            "src_1",
            "src_3"
          ],
          "confidence": "high"
        },
        {
          "claim": "Aetna’s Zepbound commercial exception policy requires prescribers to document Wegovy intolerance, contraindication, or inadequate response before Zepbound approval.",
          "evidence": [
            "src_2"
          ],
          "confidence": "high"
        },
        {
          "claim": "Payers show clear preference for therapies with measurable long-term outcomes, especially cardiovascular risk reduction and other comorbidity-linked benefits.",
          "evidence": [
            "src_1",
            "src_3"
          ],
          "confidence": "medium"
        },
        {
          "claim": "The main payer concerns are durability, adherence, and avoiding continued coverage without objective clinical response.",
          "evidence": [
            "src_1",
            "src_3"
          ],
          "confidence": "high"
        }
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"claimRecord\":{\"claims\":[{\"claim\":\"Major U.S. commercial and Medicare Advantage plans generally cover branded anti-obesity medications through pharmacy benefits, but typically only under prior authorization or exception-based programs.\",\"confidence\":\"high\",\"evidence\":[\"src_1\",\"src_2\",\"src_3\"]},{\"claim\":\"UnitedHealthcare’s commercial policy covers a broad obesity-drug portfolio, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.\",\"confidence\":\"high\",\"evidence\":[\"src_1\"]},{\"claim\":\"Payer access criteria commonly require FDA-labeled indication, BMI/age thresholds, lifestyle-program participation, and renewal-based weight-loss response milestones.\",\"confidence\":\"high\",\"evidence\":[\"src_1\",\"src_3\"]},{\"claim\":\"Aetna’s Zepbound commercial exception policy requires prescribers to document Wegovy intolerance, contraindication, or inadequate response before Zepbound approval.\",\"confidence\":\"high\",\"evidence\":[\"src_2\"]},{\"claim\":\"Payers show clear preference for therapies with measurable long-term outcomes, especially cardiovascular risk reduction and other comorbidity-linked benefits.\",\"confidence\":\"medium\",\"evidence\":[\"src_1\",\"src_3\"]},{\"claim\":\"The main payer concerns are durability, adherence, and avoiding continued coverage without objective clinical response.\",\"confidence\":\"high\",\"evidence\":[\"src_1\",\"src_3\"]}]}}",
  "providerResponseId": "resp_0eaca14299528ff8006a05f493b65881a1ba7dc66aad81ce49"
}

{
  "output": {
    "challengeOutput": {
      "caveats": [
        "The source base is too narrow to support market-wide claims about 'major U.S. commercial and Medicare Advantage plans.'",
        "Public payer policies may not reflect actual adjudication, employer carve-outs, overrides, or medical-benefit coverage.",
        "The Aetna HIDE source has metadata ambiguity; it should not anchor broad conclusions without verification.",
        "Claims about employer influence and competitor positioning are largely speculative in the current draft and should be labeled as assumptions, not findings.",
        "Claims about economic value, ROI, and outcomes-based contracting are not directly evidenced here and need external support."
      ],
      "claimLevelRevisions": [
        {
          "claim": "Major U.S. commercial and Medicare Advantage plans generally cover branded anti-obesity medications through pharmacy benefits, but typically only under prior authorization or exception-based programs.",
          "issue": "Unsupported generalization from a very small, non-representative source set (UHC + Aetna only).",
          "revision": "Some major U.S. commercial and Medicare Advantage plans cover branded anti-obesity medications, often with prior authorization or exception-based controls; this is not enough to say this is the general market pattern."
        },
        {
          "claim": "UnitedHealthcare’s commercial policy covers a broad obesity-drug portfolio, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.",
          "issue": "Mostly supported, but the wording 'broad portfolio' is a mild embellishment.",
          "revision": "UnitedHealthcare’s posted commercial policy lists multiple anti-obesity drugs, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026."
        },
        {
          "claim": "Payer access criteria commonly require FDA-labeled indication, BMI/age thresholds, lifestyle-program participation, and renewal-based weight-loss response milestones.",
          "issue": "'Commonly' is too strong for two payers and one ambiguous HIDE policy; support is indirect and limited.",
          "revision": "The reviewed payer policies require FDA-labeled indication and BMI/age thresholds, and some include lifestyle or renewal-response requirements."
        },
        {
          "claim": "Aetna’s Zepbound commercial exception policy requires prescribers to document Wegovy intolerance, contraindication, or inadequate response before Zepbound approval.",
          "issue": "Single-source support; the summary may overstate a step-therapy requirement as a firm rule.",
          "revision": "Aetna’s Zepbound commercial exception policy appears to require documentation related to Wegovy before Zepbound approval, but the exact step/exception logic should be verified from the full policy text."
        },
        {
          "claim": "Payers show clear preference for therapies with measurable long-term outcomes, especially cardiovascular risk reduction and other comorbidity-linked benefits.",
          "issue": "Inference from coverage criteria, not direct payer rationale.",
          "revision": "The posted policies suggest payers value labeled long-term outcomes such as cardiovascular risk reduction and comorbidity-linked benefits, but 'clear preference' is too strong based on this evidence set."
        },
        {
          "claim": "The main payer concerns are durability, adherence, and avoiding continued coverage without objective clinical response.",
          "issue": "Durability is supported; adherence is inferred, not directly shown.",
          "revision": "The policies indicate concern about durability and ongoing response, but adherence is more an implied concern than a directly evidenced payer priority."
        },
        {
          "claim": "Aetna’s HIDE clinical PA requires single-agent use, age and BMI criteria (including pediatric percentiles and ≥18 years adult thresholds), and documentation of comorbidities for initial and renewal approvals.",
          "issue": "Potential overread of a mixed Medicare/Medicaid source with metadata inconsistency.",
          "revision": "Aetna’s HIDE policy includes age/BMI criteria and comorbidity requirements; single-agent and renewal rules should be described only if explicitly confirmed in the policy text."
        }
      ],
      "unresolvedQuestions": [
        "How many additional national/regional payer policies were reviewed beyond UHC and Aetna?",
        "Do other major PBMs or plans show the same step edits, or do some use softer controls or exclusions?",
        "Does Aetna’s Zepbound policy truly require Wegovy failure, or is the logic more nuanced than the summary suggests?",
        "Is the HIDE policy correctly classified, and does it apply to the cited plan population as written?",
        "What direct payer evidence exists for prioritizing cardiovascular outcomes, cost offsets, or adherence/durability beyond coverage criteria?",
        "Are there documented employer-specific obesity-drug carve-outs or broader coverage cases, or is that only an industry assumption?",
        "Are there any concrete manufacturer payer decks or contract examples to support competitor claims?"
      ],
      "confidenceAdjustments": [
        {
          "claim": "Major U.S. commercial and Medicare Advantage plans generally cover branded anti-obesity medications through pharmacy benefits, but typically only under prior authorization or exception-based programs.",
          "newConfidence": "low-medium"
        },
        {
          "claim": "UnitedHealthcare’s commercial policy covers a broad obesity-drug portfolio, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.",
          "newConfidence": "medium-high"
        },
        {
          "claim": "Payer access criteria commonly require FDA-labeled indication, BMI/age thresholds, lifestyle-program participation, and renewal-based weight-loss response milestones.",
          "newConfidence": "medium"
        },
        {
          "claim": "Aetna’s Zepbound commercial exception policy requires prescribers to document Wegovy intolerance, contraindication, or inadequate response before Zepbound approval.",
          "newConfidence": "medium"
        },
        {
          "claim": "Payers show clear preference for therapies with measurable long-term outcomes, especially cardiovascular risk reduction and other comorbidity-linked benefits.",
          "newConfidence": "low-medium"
        },
        {
          "claim": "The main payer concerns are durability, adherence, and avoiding continued coverage without objective clinical response.",
          "newConfidence": "medium"
        },
        {
          "claim": "Aetna’s HIDE clinical PA requires single-agent use, age and BMI criteria (including pediatric percentiles and ≥18 years adult thresholds), and documentation of comorbidities for initial and renewal approvals.",
          "newConfidence": "low-medium"
        }
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"challengeOutput\":{\"claimLevelRevisions\":[{\"claim\":\"Major U.S. commercial and Medicare Advantage plans generally cover branded anti-obesity medications through pharmacy benefits, but typically only under prior authorization or exception-based programs.\",\"revision\":\"Some major U.S. commercial and Medicare Advantage plans cover branded anti-obesity medications, often with prior authorization or exception-based controls; this is not enough to say this is the general market pattern.\",\"issue\":\"Unsupported generalization from a very small, non-representative source set (UHC + Aetna only).\"},{\"claim\":\"UnitedHealthcare’s commercial policy covers a broad obesity-drug portfolio, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.\",\"revision\":\"UnitedHealthcare’s posted commercial policy lists multiple anti-obesity drugs, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.\",\"issue\":\"Mostly supported, but the wording 'broad portfolio' is a mild embellishment.\"},{\"claim\":\"Payer access criteria commonly require FDA-labeled indication, BMI/age thresholds, lifestyle-program participation, and renewal-based weight-loss response milestones.\",\"revision\":\"The reviewed payer policies require FDA-labeled indication and BMI/age thresholds, and some include lifestyle or renewal-response requirements.\",\"issue\":\"'Commonly' is too strong for two payers and one ambiguous HIDE policy; support is indirect and limited.\"},{\"claim\":\"Aetna’s Zepbound commercial exception policy requires prescribers to document Wegovy intolerance, contraindication, or inadequate response before Zepbound approval.\",\"revision\":\"Aetna’s Zepbound commercial exception policy appears to require documentation related to Wegovy before Zepbound approval, but the exact step/exception logic should be verified from the full policy text.\",\"issue\":\"Single-source support; the summary may overstate a step-therapy requirement as a firm rule.\"},{\"claim\":\"Payers show clear preference for therapies with measurable long-term outcomes, especially cardiovascular risk reduction and other comorbidity-linked benefits.\",\"revision\":\"The posted policies suggest payers value labeled long-term outcomes such as cardiovascular risk reduction and comorbidity-linked benefits, but 'clear preference' is too strong based on this evidence set.\",\"issue\":\"Inference from coverage criteria, not direct payer rationale.\"},{\"claim\":\"The main payer concerns are durability, adherence, and avoiding continued coverage without objective clinical response.\",\"revision\":\"The policies indicate concern about durability and ongoing response, but adherence is more an implied concern than a directly evidenced payer priority.\",\"issue\":\"Durability is supported; adherence is inferred, not directly shown.\"},{\"claim\":\"Aetna’s HIDE clinical PA requires single-agent use, age and BMI criteria (including pediatric percentiles and ≥18 years adult thresholds), and documentation of comorbidities for initial and renewal approvals.\",\"revision\":\"Aetna’s HIDE policy includes age/BMI criteria and comorbidity requirements; single-agent and renewal rules should be described only if explicitly confirmed in the policy text.\",\"issue\":\"Potential overread of a mixed Medicare/Medicaid source with metadata inconsistency.\"}],\"confidenceAdjustments\":[{\"claim\":\"Major U.S. commercial and Medicare Advantage plans generally cover branded anti-obesity medications through pharmacy benefits, but typically only under prior authorization or exception-based programs.\",\"newConfidence\":\"low-medium\"},{\"claim\":\"UnitedHealthcare’s commercial policy covers a broad obesity-drug portfolio, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.\",\"newConfidence\":\"medium-high\"},{\"claim\":\"Payer access criteria commonly require FDA-labeled indication, BMI/age thresholds, lifestyle-program participation, and renewal-based weight-loss response milestones.\",\"newConfidence\":\"medium\"},{\"claim\":\"Aetna’s Zepbound commercial exception policy requires prescribers to document Wegovy intolerance, contraindication, or inadequate response before Zepbound approval.\",\"newConfidence\":\"medium\"},{\"claim\":\"Payers show clear preference for therapies with measurable long-term outcomes, especially cardiovascular risk reduction and other comorbidity-linked benefits.\",\"newConfidence\":\"low-medium\"},{\"claim\":\"The main payer concerns are durability, adherence, and avoiding continued coverage without objective clinical response.\",\"newConfidence\":\"medium\"},{\"claim\":\"Aetna’s HIDE clinical PA requires single-agent use, age and BMI criteria (including pediatric percentiles and ≥18 years adult thresholds), and documentation of comorbidities for initial and renewal approvals.\",\"newConfidence\":\"low-medium\"}],\"caveats\":[\"The source base is too narrow to support market-wide claims about 'major U.S. commercial and Medicare Advantage plans.'\",\"Public payer policies may not reflect actual adjudication, employer carve-outs, overrides, or medical-benefit coverage.\",\"The Aetna HIDE source has metadata ambiguity; it should not anchor broad conclusions without verification.\",\"Claims about employer influence and competitor positioning are largely speculative in the current draft and should be labeled as assumptions, not findings.\",\"Claims about economic value, ROI, and outcomes-based contracting are not directly evidenced here and need external support.\"],\"unresolvedQuestions\":[\"How many additional national/regional payer policies were reviewed beyond UHC and Aetna?\",\"Do other major PBMs or plans show the same step edits, or do some use softer controls or exclusions?\",\"Does Aetna’s Zepbound policy truly require Wegovy failure, or is the logic more nuanced than the summary suggests?\",\"Is the HIDE policy correctly classified, and does it apply to the cited plan population as written?\",\"What direct payer evidence exists for prioritizing cardiovascular outcomes, cost offsets, or adherence/durability beyond coverage criteria?\",\"Are there documented employer-specific obesity-drug carve-outs or broader coverage cases, or is that only an industry assumption?\",\"Are there any concrete manufacturer payer decks or contract examples to support competitor claims?\"]}}",
  "providerResponseId": "resp_020547befc8e800b006a05f496b504819cac423d6c8ea55444"
}

{
  "output": {
    "calibratedClaimRecord": {
      "claims": [
        {
          "claim": "Major U.S. commercial and Medicare Advantage plans generally cover branded anti-obesity medications through pharmacy benefits, but typically only under prior authorization or exception-based programs.",
          "evidence": [
            "src_1",
            "src_2",
            "src_3"
          ],
          "evidenceCount": 3,
          "isUnsupported": true,
          "newConfidence": "low-medium",
          "humanCorrection": "Some major U.S. commercial and Medicare Advantage plans cover branded anti-obesity medications, often with prior authorization or exception-based controls; this is not enough to say this is the general market pattern.",
          "requiresHumanReview": true,
          "supportCountBelowThreshold": false
        },
        {
          "claim": "UnitedHealthcare’s commercial policy covers a broad obesity-drug portfolio, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.",
          "evidence": [
            "src_1"
          ],
          "evidenceCount": 1,
          "isUnsupported": false,
          "newConfidence": "medium-high",
          "humanCorrection": "UnitedHealthcare’s posted commercial policy lists multiple anti-obesity drugs, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.",
          "requiresHumanReview": true,
          "supportCountBelowThreshold": true
        },
        {
          "claim": "Payer access criteria commonly require FDA-labeled indication, BMI/age thresholds, lifestyle-program participation, and renewal-based weight-loss response milestones.",
          "evidence": [
            "src_1",
            "src_3"
          ],
          "evidenceCount": 2,
          "isUnsupported": true,
          "newConfidence": "medium",
          "humanCorrection": "The reviewed payer policies require FDA-labeled indication and BMI/age thresholds, and some include lifestyle or renewal-response requirements.",
          "requiresHumanReview": true,
          "supportCountBelowThreshold": false
        },
        {
          "claim": "Aetna’s Zepbound commercial exception policy requires prescribers to document Wegovy intolerance, contraindication, or inadequate response before Zepbound approval.",
          "evidence": [
            "src_2"
          ],
          "evidenceCount": 1,
          "isUnsupported": false,
          "newConfidence": "medium",
          "humanCorrection": "Aetna’s Zepbound commercial exception policy appears to require documentation related to Wegovy before Zepbound approval, but the exact step/exception logic should be verified from the full policy text.",
          "requiresHumanReview": true,
          "supportCountBelowThreshold": true
        },
        {
          "claim": "Payers show clear preference for therapies with measurable long-term outcomes, especially cardiovascular risk reduction and other comorbidity-linked benefits.",
          "evidence": [
            "src_1",
            "src_3"
          ],
          "evidenceCount": 2,
          "isUnsupported": true,
          "newConfidence": "low-medium",
          "humanCorrection": "The posted policies suggest payers value labeled long-term outcomes such as cardiovascular risk reduction and comorbidity-linked benefits, but 'clear preference' is too strong based on this evidence set.",
          "requiresHumanReview": true,
          "supportCountBelowThreshold": false
        },
        {
          "claim": "The main payer concerns are durability, adherence, and avoiding continued coverage without objective clinical response.",
          "evidence": [
            "src_1",
            "src_3"
          ],
          "evidenceCount": 2,
          "isUnsupported": false,
          "newConfidence": "medium",
          "humanCorrection": "The policies indicate concern about durability and ongoing response, but adherence is more an implied concern than a directly evidenced payer priority.",
          "requiresHumanReview": true,
          "supportCountBelowThreshold": false
        }
      ]
    }
  },
  "status": "completed",
  "rawProviderText": "{\"calibratedClaimRecord\":{\"claims\":[{\"claim\":\"Major U.S. commercial and Medicare Advantage plans generally cover branded anti-obesity medications through pharmacy benefits, but typically only under prior authorization or exception-based programs.\",\"evidence\":[\"src_1\",\"src_2\",\"src_3\"],\"evidenceCount\":3,\"supportCountBelowThreshold\":false,\"isUnsupported\":true,\"requiresHumanReview\":true,\"newConfidence\":\"low-medium\",\"humanCorrection\":\"Some major U.S. commercial and Medicare Advantage plans cover branded anti-obesity medications, often with prior authorization or exception-based controls; this is not enough to say this is the general market pattern.\"},{\"claim\":\"UnitedHealthcare’s commercial policy covers a broad obesity-drug portfolio, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.\",\"evidence\":[\"src_1\"],\"evidenceCount\":1,\"supportCountBelowThreshold\":true,\"isUnsupported\":false,\"requiresHumanReview\":true,\"newConfidence\":\"medium-high\",\"humanCorrection\":\"UnitedHealthcare’s posted commercial policy lists multiple anti-obesity drugs, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.\"},{\"claim\":\"Payer access criteria commonly require FDA-labeled indication, BMI/age thresholds, lifestyle-program participation, and renewal-based weight-loss response milestones.\",\"evidence\":[\"src_1\",\"src_3\"],\"evidenceCount\":2,\"supportCountBelowThreshold\":false,\"isUnsupported\":true,\"requiresHumanReview\":true,\"newConfidence\":\"medium\",\"humanCorrection\":\"The reviewed payer policies require FDA-labeled indication and BMI/age thresholds, and some include lifestyle or renewal-response requirements.\"},{\"claim\":\"Aetna’s Zepbound commercial exception policy requires prescribers to document Wegovy intolerance, contraindication, or inadequate response before Zepbound approval.\",\"evidence\":[\"src_2\"],\"evidenceCount\":1,\"supportCountBelowThreshold\":true,\"isUnsupported\":false,\"requiresHumanReview\":true,\"newConfidence\":\"medium\",\"humanCorrection\":\"Aetna’s Zepbound commercial exception policy appears to require documentation related to Wegovy before Zepbound approval, but the exact step/exception logic should be verified from the full policy text.\"},{\"claim\":\"Payers show clear preference for therapies with measurable long-term outcomes, especially cardiovascular risk reduction and other comorbidity-linked benefits.\",\"evidence\":[\"src_1\",\"src_3\"],\"evidenceCount\":2,\"supportCountBelowThreshold\":false,\"isUnsupported\":true,\"requiresHumanReview\":true,\"newConfidence\":\"low-medium\",\"humanCorrection\":\"The posted policies suggest payers value labeled long-term outcomes such as cardiovascular risk reduction and comorbidity-linked benefits, but 'clear preference' is too strong based on this evidence set.\"},{\"claim\":\"The main payer concerns are durability, adherence, and avoiding continued coverage without objective clinical response.\",\"evidence\":[\"src_1\",\"src_3\"],\"evidenceCount\":2,\"supportCountBelowThreshold\":false,\"isUnsupported\":false,\"requiresHumanReview\":true,\"newConfidence\":\"medium\",\"humanCorrection\":\"The policies indicate concern about durability and ongoing response, but adherence is more an implied concern than a directly evidenced payer priority.\"}]}}",
  "providerResponseId": "resp_08de2ed1f306093a006a05f4a10afc819fbeee94739c56098b"
}

{
  "output": {
    "finalDeliverable": {
      "executiveSummary": "Bottom line: evidence is too thin to make broad market-wide claims, but the reviewed policies show that some major U.S. commercial and Medicare Advantage plans cover anti-obesity drugs with prior authorization or exception-based controls, and access is tightly managed.\n\nTop findings:\n- UnitedHealthcare’s posted commercial policy lists multiple anti-obesity drugs, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.\n- The reviewed payer policies require FDA-labeled indication and BMI/age thresholds, and some include lifestyle or renewal-response requirements.\n- Aetna’s Zepbound commercial exception policy appears to require documentation related to Wegovy before Zepbound approval, but the exact step/exception logic should be verified.\n- The policies suggest payers value labeled long-term outcomes such as cardiovascular risk reduction and comorbidity-linked benefits, but direct payer rationale is limited.\n- The main payer concerns evidenced here are durability and ongoing response; adherence is more implied than directly shown.\n- Claims about employer influence, competitor positioning, and outcomes-based contracting remain largely speculative in this evidence set and should be treated as assumptions, not findings.",
      "supplementalMaterial": {
        "depth": "Medium-depth, with prioritization of current, decision-relevant payer intelligence and recent policy shifts",
        "audience": [
          "Market access leaders",
          "Commercial strategy teams",
          "Payer strategy teams",
          "Brand teams"
        ],
        "objective": "Assess current and evolving U.S. payer coverage policies for anti-obesity medications; identify drivers of favorable versus restrictive access; clarify evidence expectations for formulary inclusion and tiering; understand how payers define and measure value; and identify access barriers and differentiation opportunities.",
        "topic_type": "Market access / payer policy research",
        "assumptions": [
          "The primary focus is U.S. payer coverage for prescription anti-obesity pharmacotherapies rather than non-pharmacologic obesity management.",
          "Commercial and Medicare Advantage coverage are the most relevant payer segments; Medicaid and self-insured employer nuances are secondary unless they materially shape access.",
          "Evidence from both published sources and gray literature is in scope, including payer policy documents, conference content, and advisory-board insights.",
          "Coverage differences between pharmacy benefit and medical benefit should be captured when identifiable.",
          "Direct payer quotations may not be available for all payers; summarized perspectives are acceptable when verbatim quotes cannot be sourced.",
          "Recent means approximately the prior 12–18 months from the current date, unless older policy context is needed for comparison.",
          "Competitor analysis is limited to payer-facing value propositions rather than a full commercial review of all obesity brands."
        ],
        "geographies": [
          "United States"
        ],
        "target_topic": "U.S. payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies",
        "time_horizon": "Current state with emphasis on policy and coverage changes from the last 12–18 months",
        "output_format": "Consulting-style research brief with qualitative synthesis supported by policy documents, gray literature, and payer quotes where available",
        "sourceEvidence": [
          "UnitedHealthcare commercial prior authorization/notification policy for weight-loss medications",
          "Aetna commercial Zepbound exception policy",
          "Aetna Medicare HIDE weight-loss prior authorization criteria"
        ],
        "target_entities": [
          "National commercial health plans",
          "Regional commercial health plans",
          "Medicare Advantage plans",
          "Pharmacy benefit managers (PBMs)",
          "Employer-sponsored health plans",
          "Manufacturers / competitors in anti-obesity therapeutics"
        ],
        "decision_context": "Inform market access strategy, payer value proposition development, and coverage/contracting approach for anti-obesity medications in the U.S. payer landscape.",
        "research_question": "How do major U.S. commercial and Medicare Advantage plans cover anti-obesity medications, what utilization management is most common, what evidence do payers prioritize for coverage and value assessment, and how are employers and competitors influencing access decisions?",
        "priority_dimension": [
          "Coverage status and formulary positioning",
          "Utilization management requirements",
          "Clinical and economic evidence requirements",
          "Long-term outcomes evidence (e.g., cardiovascular risk reduction, cost offsets)",
          "Adherence, discontinuation, and real-world effectiveness concerns",
          "Employer influence on coverage decisions",
          "Unmet payer needs",
          "Competitor value propositioning",
          "Innovative contracting models"
        ]
      }
    }
  },
  "status": "completed",
  "rawProviderText": "{\"finalDeliverable\":{\"executiveSummary\":\"Bottom line: evidence is too thin to make broad market-wide claims, but the reviewed policies show that some major U.S. commercial and Medicare Advantage plans cover anti-obesity drugs with prior authorization or exception-based controls, and access is tightly managed.\\n\\nTop findings:\\n- UnitedHealthcare’s posted commercial policy lists multiple anti-obesity drugs, including Wegovy, Zepbound, Saxenda, Qsymia, Contrave, and Xenical, effective May 1, 2026.\\n- The reviewed payer policies require FDA-labeled indication and BMI/age thresholds, and some include lifestyle or renewal-response requirements.\\n- Aetna’s Zepbound commercial exception policy appears to require documentation related to Wegovy before Zepbound approval, but the exact step/exception logic should be verified.\\n- The policies suggest payers value labeled long-term outcomes such as cardiovascular risk reduction and comorbidity-linked benefits, but direct payer rationale is limited.\\n- The main payer concerns evidenced here are durability and ongoing response; adherence is more implied than directly shown.\\n- Claims about employer influence, competitor positioning, and outcomes-based contracting remain largely speculative in this evidence set and should be treated as assumptions, not findings.\",\"supplementalMaterial\":{\"research_question\":\"How do major U.S. commercial and Medicare Advantage plans cover anti-obesity medications, what utilization management is most common, what evidence do payers prioritize for coverage and value assessment, and how are employers and competitors influencing access decisions?\",\"objective\":\"Assess current and evolving U.S. payer coverage policies for anti-obesity medications; identify drivers of favorable versus restrictive access; clarify evidence expectations for formulary inclusion and tiering; understand how payers define and measure value; and identify access barriers and differentiation opportunities.\",\"topic_type\":\"Market access / payer policy research\",\"target_topic\":\"U.S. payer coverage, access, and value assessment trends for anti-obesity pharmacotherapies\",\"target_entities\":[\"National commercial health plans\",\"Regional commercial health plans\",\"Medicare Advantage plans\",\"Pharmacy benefit managers (PBMs)\",\"Employer-sponsored health plans\",\"Manufacturers / competitors in anti-obesity therapeutics\"],\"geographies\":[\"United States\"],\"time_horizon\":\"Current state with emphasis on policy and coverage changes from the last 12–18 months\",\"decision_context\":\"Inform market access strategy, payer value proposition development, and coverage/contracting approach for anti-obesity medications in the U.S. payer landscape.\",\"priority_dimension\":[\"Coverage status and formulary positioning\",\"Utilization management requirements\",\"Clinical and economic evidence requirements\",\"Long-term outcomes evidence (e.g., cardiovascular risk reduction, cost offsets)\",\"Adherence, discontinuation, and real-world effectiveness concerns\",\"Employer influence on coverage decisions\",\"Unmet payer needs\",\"Competitor value propositioning\",\"Innovative contracting models\"],\"output_format\":\"Consulting-style research brief with qualitative synthesis supported by policy documents, gray literature, and payer quotes where available\",\"depth\":\"Medium-depth, with prioritization of current, decision-relevant payer intelligence and recent policy shifts\",\"audience\":[\"Market access leaders\",\"Commercial strategy teams\",\"Payer strategy teams\",\"Brand teams\"],\"assumptions\":[\"The primary focus is U.S. payer coverage for prescription anti-obesity pharmacotherapies rather than non-pharmacologic obesity management.\",\"Commercial and Medicare Advantage coverage are the most relevant payer segments; Medicaid and self-insured employer nuances are secondary unless they materially shape access.\",\"Evidence from both published sources and gray literature is in scope, including payer policy documents, conference content, and advisory-board insights.\",\"Coverage differences between pharmacy benefit and medical benefit should be captured when identifiable.\",\"Direct payer quotations may not be available for all payers; summarized perspectives are acceptable when verbatim quotes cannot be sourced.\",\"Recent means approximately the prior 12–18 months from the current date, unless older policy context is needed for comparison.\",\"Competitor analysis is limited to payer-facing value propositions rather than a full commercial review of all obesity brands.\"],\"sourceEvidence\":[\"UnitedHealthcare commercial prior authorization/notification policy for weight-loss medications\",\"Aetna commercial Zepbound exception policy\",\"Aetna Medicare HIDE weight-loss prior authorization criteria\"]}}}",
  "providerResponseId": "resp_025993457dd1f9d2006a05f4b5aea48193b582e933e50465e7"
}